CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Durata Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Durata Therapeutics Inc
Suite 2550, 200 South Wacker Drive
Phone: (312) 219-7000p:312 219-7000 CHICAGO, IL  60606  United States Ticker: DRTXDRTX

This company ceased filing statements with the SEC on 11/28/2014.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201412/31/2013YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Richard U.De Schutter 73 7/1/2012 7/1/2012
Chief Executive Officer, Director Paul R.Edick 59 7/1/2012 7/1/2012
Chief Financial Officer, Chief Operating Officer Corey N.Fishman 49 7/1/2012 7/1/2012
7 additional Officers and Directors records available in full report.

Business Names
Business Name
DRTX
Durata Therapeutics Holding C.V.
Durata Therapeutics International B.V.
Durata Therapeutics Limited
Durata Therapeutics U.S. Limited
Vicuron Pharmaceuticals Inc.

General Information
Stock Exchange: NASD
Federal Tax Id: 271247903
Fax Number: (302) 655-5049
Email Address: info@duratatherapeutics.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023